James Thomas, MD
Cardiovascular Disease · Conway, ARNPI 1700845427
Payments from drug & device makers
What this record shows
This record is dominated by other: $23,583 of the $35,263 with a category attached, or 66.9%. Angiodynamics, Inc. accounts for 66.9% of it on its own, with 40 other manufacturers making up the rest. 2025 is the largest year on record at $24,592, 9.2 times the $2,686 reported in 2019. Among cardiovascular disease clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 480 payments — averaging $73.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$24K
- Abbott$1K
- Novartis$1K
- Johnson & Johnson$953
- Bard Peripheral Vascular, Inc.$893
- Amgen$874
- plus $6K from 35 others
What the payments were for
- Travel & lodging$3091%
- Food & beverage$11,22332%
- Education$1480%
- Other$23,58367%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$23,583
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$687
- PANTHERIS$410
- VENOVO$309
- COROFLOW$146
- EKOSONIC$145
- LUTONIX$144
- ESPRIT$141
- Senza$137
- Absorb GT1$115
- XARELTO$114
- Diamondback Peripheral$111
- Diamondback Coronary$111
- ENTRESTO$107
- ASAHI PTCA Guide Wire$104
How this compares
$35,263 in reported general payments places this provider in the 90th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 701 | $482,000 |
| XareltoRivaroxaban | 589 | $470,633 |
| MultaqDronedarone Hcl | 169 | $159,914 |
| EntrestoSacubitril/Valsartan | 143 | $117,551 |
| FarxigaDapagliflozin Propanediol | 110 | $74,191 |
| Propafenone Hcl ErPropafenone Hcl | 314 | $48,545 |
| Prasugrel Hcl | 682 | $42,755 |
| Repatha SureclickEvolocumab | 45 | $37,812 |
| JardianceEmpagliflozin | 27 | $22,469 |
| Repatha SyringeEvolocumab | 35 | $20,446 |
| BrilintaTicagrelor | 30 | $17,423 |
| Propafenone Hcl | 338 | $14,664 |
| Atenolol | 2,213 | $11,332 |
| Nifedipine ErNifedipine | 528 | $11,075 |
| Ranolazine ErRanolazine | 146 | $9,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $805 | $482,000701 claims |
| Johnson & JohnsonXarelto | $953 | $470,633589 claims |
| Sanofi-aventis U.S. LLCMultaq | $428 | $159,914169 claims |
| NovartisEntresto | $1,168 | $117,551143 claims |
| AstraZenecaFarxiga, Brilinta | $349 | $91,615140 claims |
| Boehringer IngelheimJardiance | $240 | $22,46927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Conway
- Faheemullah BegConway$10K
- Ian CawichLittle Rock$294K
- Barry TedderJonesboro$130K
- Harvinder DodEl Dorado$126K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Julio SchwarzFort Smith$70K
- Maximiliano ArroyoJonesboro$46K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.